Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase 1, Randomized, Observer-blind, Controlled Study to Assess the Safety and Immunogenicity of Novel Live Attenuated Type 1 and Type 3 Oral Poliomyelitis Vaccines in Healthy Adults

NCT04529538 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT04529538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04529538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase 1, Randomized, Observer-blind, Controlled Study to Assess the Safety and Immunogenicity of Novel Live Attenuated Type 1 and Type 3 Oral Poliomyelitis Vaccines in Healthy Adults
Lead sponsor
PATH
Phase
Phase 1
Overall status
Completed
Start date
March 26, 2021
Completion date
February 17, 2023
Enrollment
226 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis